Allogene Therapeutics, Inc. - Common Stock (ALLO)
CUSIP: 019770106
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 228,416,724
- Total 13F shares
- 162,689,328
- Share change
- +102,529
- Total reported value
- $222,787,071
- Put/Call ratio
- 16%
- Price per share
- $1.37
- Number of holders
- 169
- Value change
- +$240,755
- Number of buys
- 76
- Number of sells
- 66
Quarterly Holders Quick Answers
What is CUSIP 019770106?
CUSIP 019770106 identifies ALLO - Allogene Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 019770106:
Top shareholders of ALLO - Allogene Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| TPG GP A, LLC |
3/4/5
13F
|
10%+ Owner · Company |
8.2%
from 13F
|
18,716,306
|
$59,413,042 | — | 12 Jan 2022 | |
| PFIZER INC |
13D/G
13F
|
Company |
9%
|
22,032,040
|
$30,183,895 | $0 | 06 Nov 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.3%
from 13D/G
|
17,514,674
|
$21,718,195 | — | 30 Sep 2025 | |
| Arie Belldegrun |
13D/G
|
Arie Belldegrun, M.D. |
5.8%
|
13,248,170
|
$18,149,993 | +$794,362 | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
13D/G
|
Company · Kenneth Griffin |
6.1%
from 13D/G
|
13,971,557
|
$17,324,731 | — | 30 Sep 2025 | |
| Lynx1 Capital Management LP |
13D/G
13F
|
Company |
5.2%
|
10,874,723
|
$16,747,073 | $0 | 31 Dec 2024 | |
| David D. Chang |
13D/G
|
David D. Chang, M.D., Ph.D. |
5.2%
|
12,101,223
|
$16,578,676 | +$1,186,838 | 31 Dec 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
4.9%
|
10,225,851
|
$15,747,811 | -$20,861,062 | 28 Feb 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.9%
|
9,020,770
|
$11,185,755 | — | 30 Sep 2025 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
3.1%
|
7,079,308
|
$8,778,342 | — | 30 Sep 2025 | |
| Eric Thomas Schmidt |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
2,447,772
mixed-class rows
|
$6,396,524 | — | 22 Mar 2023 | |
| Woodline Partners LP |
13F
|
Company |
1.9%
|
4,360,608
|
$5,407,154 | — | 30 Sep 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.7%
|
3,868,750
|
$4,797,250 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
3,833,885
|
$4,754,796 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.6%
|
3,677,474
|
$4,561,000 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
1.6%
|
3,571,157
|
$4,428,235 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.5%
|
3,390,026
|
$4,203,632 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.5%
|
3,383,644
|
$4,195,719 | — | 30 Sep 2025 | |
| Patient Square Capital LP |
13F
|
Company |
1.3%
|
2,981,396
|
$3,696,931 | — | 30 Sep 2025 | |
| Wildcat Capital Management, LLC |
13F
|
Company |
1.3%
|
2,920,787
|
$3,621,776 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.3%
|
2,893,812
|
$3,588,327 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.2%
|
2,781,600
|
$3,449,184 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.2%
|
2,755,378
|
$3,416,669 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.92%
|
2,090,753
|
$2,592,869 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.81%
|
1,853,554
|
$2,298,407 | — | 30 Sep 2025 | |
| Vida Ventures Advisors, LLC |
13F
|
Company |
0.79%
|
1,798,163
|
$2,229,722 | — | 30 Sep 2025 | |
| Alison Moore |
3/4/5
|
Chief Technical Officer |
—
mixed-class rows
|
1,105,469
mixed-class rows
|
$2,135,517 | — | 22 Mar 2023 | |
| Aberdeen Group plc |
13F
|
Company |
0.69%
|
1,582,265
|
$1,962,009 | — | 30 Sep 2025 | |
| Veer Bhavnagri |
3/4/5
|
General Counsel |
—
class O/S missing
|
556,049
|
$1,765,122 | — | 14 Mar 2023 | |
| Rafael Amado |
3/4/5
|
EVP of R&D |
—
class O/S missing
|
541,946
|
$1,720,353 | — | 07 Oct 2022 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.6%
|
1,380,118
|
$1,711,346 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.57%
|
1,299,166
|
$1,610,966 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.56%
|
1,279,628
|
$1,586,739 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.53%
|
1,215,773
|
$1,507,559 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.53%
|
1,203,708
|
$1,492,598 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.51%
|
1,165,280
|
$1,444,947 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.48%
|
1,098,569
|
$1,363,000 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.43%
|
974,320
|
$1,208,157 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.4%
|
908,725
|
$1,126,819 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.39%
|
894,314
|
$1,108,949 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.34%
|
774,203
|
$960,012 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.26%
|
598,997
|
$742,756 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.26%
|
594,099
|
$736,683 | — | 30 Sep 2025 | |
| Franz B. Humer |
3/4/5
|
Director |
—
mixed-class rows
|
402,907
mixed-class rows
|
$664,215 | — | 18 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.23%
|
533,809
|
$659,000 | — | 30 Sep 2025 | |
| ZACKS INVESTMENT MANAGEMENT |
13F
|
Company |
0.23%
|
526,132
|
$652,404 | — | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.23%
|
525,313
|
$651,388 | — | 30 Sep 2025 | |
| Moloney Securities Asset Management, LLC |
13F
|
Company |
0.23%
|
514,000
|
$637,360 | — | 30 Sep 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.21%
|
489,977
|
$607,571 | — | 30 Sep 2025 | |
| Cerity Partners LLC |
13F
|
Company |
0.2%
|
466,732
|
$578,748 | — | 30 Sep 2025 |
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2025
As of 31 Dec 2025,
Allogene Therapeutics, Inc. - Common Stock (ALLO) was held by
169 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
162,689,328 shares.
The largest 10 holders included
Pfizer Inc, TPG GP A, LLC, BlackRock, Inc., CITADEL ADVISORS LLC, VANGUARD GROUP INC, PRIMECAP MANAGEMENT CO/CA/, Patient Square Capital LP, GEODE CAPITAL MANAGEMENT, LLC, Frazier Life Sciences Management, L.P., and Woodline Partners LP.
This page lists
169
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
167
Q4 2025 holders
169
Holder diff
2
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.